Specifically, our data provide initial evidence that (a) IL-17F signaling also plays a critical role in NAFLD pathogenesis and (b) the IL-17 axis plays a broad role in multiple models of NAFLD via modulation of hepatic inflammation. This evidence concerns the gene IL17F and metabolic dysfunction-associated steatotic liver disease.